Cargando…
Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours
Tigilanol tiglate (TT) is a novel small molecule registered as a veterinary pharmaceutical for intratumoural treatment of canine mast cell tumours (MCTs). The drug has a multifactorial mode of action resulting in rapid destruction of the treated tumour by haemorrhagic necrosis and subsequent slough...
Autores principales: | De Ridder, Thomas, Reddell, Paul, Jones, Pamela, Brown, Graham, Campbell, Justine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715915/ https://www.ncbi.nlm.nih.gov/pubmed/34977208 http://dx.doi.org/10.3389/fvets.2021.764800 |
Ejemplares similares
-
Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate
por: Brown, Graham K., et al.
Publicado: (2021) -
Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate
por: Brown, Graham K., et al.
Publicado: (2022) -
Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors
por: Miller, Jane, et al.
Publicado: (2019) -
Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses
por: De Ridder, Thomas, et al.
Publicado: (2020) -
Recurrence‐free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate
por: Jones, Pamela D., et al.
Publicado: (2020)